AGIO | Agios Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-3.97 Insider Own1.35% Shs Outstand55.27M Perf Week5.92%
Market Cap1.47B Forward P/E- EPS next Y-5.50 Insider Trans-15.67% Shs Float54.23M Perf Month5.01%
Income-218.00M PEG- EPS next Q-1.56 Inst Own109.02% Short Float / Ratio10.68% / 12.01 Perf Quarter13.84%
Sales19.00M P/S77.44 EPS this Y28.30% Inst Trans-3.05% Short Interest5.79M Perf Half Y-14.91%
Book/sh18.76 P/B1.43 EPS next Y11.30% ROA-18.10% Target Price37.40 Perf Year36.28%
Cash/sh13.47 P/C1.99 EPS next 5Y39.00% ROE-20.20% 52W Range16.75 - 34.76 Perf YTD-4.49%
Dividend- P/FCF- EPS past 5Y8.90% ROI-22.80% 52W High-22.84% Beta0.94
Dividend %- Quick Ratio17.30 Sales past 5Y-19.80% Gross Margin89.90% 52W Low60.12% ATR1.00
Employees389 Current Ratio17.50 Sales Q/Q600.00% Oper. Margin- RSI (14)63.41 Volatility3.98% 3.56%
OptionableYes Debt/Eq0.00 EPS Q/Q15.60% Profit Margin- Rel Volume0.78 Prev Close26.06
ShortableYes LT Debt/Eq0.00 EarningsMay 04 BMO Payout- Avg Volume482.26K Price26.82
Recom2.20 SMA203.67% SMA5012.31% SMA200-0.61% Volume376,827 Change2.92%
Date Action Analyst Rating Change Price Target Change
Feb-03-23Initiated Piper Sandler Overweight $41
Nov-17-22Upgrade Goldman Sell → Neutral $17 → $32
Jul-27-22Upgrade SVB Leerink Mkt Perform → Outperform $33
Dec-03-21Initiated BofA Securities Buy $54
Jul-30-21Downgrade Goldman Neutral → Sell $58 → $39
Jul-01-21Initiated Raymond James Mkt Perform
Jun-10-21Initiated H.C. Wainwright Buy $88
Mar-01-21Upgrade SVB Leerink Mkt Perform → Outperform $50
Mar-01-21Downgrade JP Morgan Overweight → Neutral $64 → $54
Feb-26-21Downgrade SVB Leerink Outperform → Mkt Perform
Jun-05-23 07:00AM
May-30-23 09:45AM
May-25-23 09:55AM
May-11-23 10:00AM
09:55AM Loading…
May-09-23 09:55AM
May-08-23 07:55AM
May-05-23 10:50AM
May-04-23 11:23PM
Apr-25-23 07:00AM
Apr-19-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 08:00AM
01:19PM Loading…
Apr-09-23 01:19PM
Apr-03-23 07:00AM
Mar-15-23 11:44AM
Mar-11-23 09:10AM
Mar-05-23 05:20AM
Mar-02-23 08:26AM
Feb-28-23 07:00AM
Feb-24-23 12:00PM
Feb-23-23 08:45AM
Feb-09-23 09:40AM
Feb-02-23 07:00AM
Jan-15-23 08:56AM
08:00PM Loading…
Jan-08-23 08:00PM
Jan-03-23 05:57PM
Dec-24-22 10:07AM
Dec-21-22 08:00AM
Dec-11-22 07:00PM
Dec-10-22 06:30PM
Dec-06-22 07:00AM
Nov-30-22 08:00AM
Nov-17-22 05:52AM
Nov-11-22 11:03AM
Nov-10-22 04:01PM
Nov-09-22 05:36AM
Nov-04-22 12:20PM
Nov-03-22 09:00AM
Oct-27-22 04:01PM
Oct-20-22 07:00AM
Oct-02-22 09:44AM
Sep-26-22 07:13PM
Sep-19-22 07:00AM
Sep-16-22 06:41AM
Sep-06-22 08:05AM
Sep-02-22 04:02PM
Aug-24-22 07:00AM
Aug-18-22 06:35PM
Aug-15-22 08:00AM
Aug-11-22 06:35PM
Aug-08-22 06:36PM
Aug-05-22 12:20PM
Aug-04-22 08:45AM
Jul-14-22 07:00AM
Jul-12-22 04:01PM
Jun-13-22 06:30AM
Jun-10-22 10:30AM
Jun-02-22 05:39PM
May-17-22 12:13PM
May-16-22 04:15PM
May-12-22 10:00AM
May-10-22 07:00AM
May-07-22 09:02AM
May-05-22 08:15AM
Apr-21-22 07:00AM
Apr-14-22 08:34AM
Mar-01-22 08:35AM
Feb-28-22 07:00AM
Feb-24-22 05:49PM
Feb-23-22 12:57PM
Feb-18-22 10:29AM
Feb-17-22 03:41PM
Feb-10-22 07:00AM
Feb-08-22 01:38PM
Jan-18-22 02:57PM
Jan-10-22 01:38PM
Dec-22-21 07:00AM
Dec-21-21 04:27AM
Dec-17-21 11:38PM
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOUSE JACQUALYN ADirectorApr 08Option Exercise0.0015,933098,515Apr 12 04:17 PM
Schenkein David PDirectorApr 03Option Exercise9.0516,363148,085134,242Apr 05 04:03 PM
Schenkein David PDirectorApr 03Sale22.8516,363373,895117,879Apr 05 04:03 PM
Schenkein David PDirectorMar 27Option Exercise9.0520,000181,000137,879Mar 29 09:30 PM
Schenkein David PDirectorMar 27Sale22.1520,000443,000117,879Mar 29 09:30 PM
Schenkein David PDirectorMar 13Option Exercise9.0520,000181,000137,879Mar 15 05:11 PM
Schenkein David PDirectorMar 13Sale22.4920,000449,817117,879Mar 15 05:11 PM
Washburn Theodore James Jr.Principal Accounting OfficerMar 03Sale24.2950412,2422,741Mar 07 04:02 PM
Washburn Theodore James Jr.Principal Accounting OfficerMar 01Option Exercise0.0077703,518Mar 03 04:08 PM
Gheuens SarahChief Medical OfficerMar 01Option Exercise0.003,833021,250Mar 03 04:05 PM
Schenkein David PDirectorFeb 27Option Exercise9.0520,000181,000137,879Mar 01 04:06 PM
Schenkein David PDirectorFeb 27Sale25.3720,000507,400117,879Mar 01 04:06 PM
Washburn Theodore James Jr.Principal Accounting OfficerFeb 16Sale27.212336,3402,668Feb 21 04:05 PM
Washburn Theodore James Jr.Principal Accounting OfficerFeb 14Option Exercise0.0036003,532Feb 16 04:04 PM
FOUSE JACQUALYN ADirectorFeb 14Option Exercise0.0011,333086,230Feb 16 04:03 PM
Burns James WilliamChief Legal OfficerFeb 14Option Exercise0.001,738024,147Feb 16 04:04 PM
Washburn Theodore James Jr.Principal Accounting OfficerFeb 14Sale28.5950414,4092,901Feb 16 04:04 PM
Schenkein David PDirectorFeb 13Option Exercise9.0520,000181,000137,879Feb 15 04:03 PM
Schenkein David PDirectorFeb 13Sale28.6220,000572,400117,879Feb 15 04:03 PM
Burns James WilliamChief Legal OfficerFeb 10Option Exercise0.001,834023,052Feb 14 04:07 PM
Washburn Theodore James Jr.Principal Accounting OfficerFeb 10Option Exercise0.0077703,445Feb 14 04:06 PM
Schenkein David PDirectorJan 30Option Exercise9.0520,000181,000137,879Feb 01 04:04 PM
Schenkein David PDirectorJan 30Sale29.3320,000586,578117,879Feb 01 04:04 PM
Schenkein David PDirectorJan 17Option Exercise9.0520,000181,000137,879Jan 19 04:03 PM
Schenkein David PDirectorJan 17Sale28.8520,000577,093117,879Jan 19 04:03 PM
Burns James WilliamChief Legal OfficerDec 23Option Exercise0.008,750023,815Dec 28 04:05 PM
Gheuens SarahChief Medical OfficerDec 23Option Exercise0.009,375018,388Dec 28 04:05 PM
Gheuens SarahChief Medical OfficerDec 02Option Exercise0.0083309,261Dec 06 04:14 PM
Poddar RichaChief Commercial OfficerOct 15Option Exercise0.005,00009,993Oct 18 04:17 PM